Analysts Issue Forecasts for Rezolute FY2025 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Rezolute in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($0.97) per share for the year. The consensus estimate for Rezolute’s current full-year earnings is ($0.99) per share.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13.

Several other research analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price target on shares of Rezolute in a report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and issued a $112.00 price target on shares of Rezolute in a report on Monday, November 4th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $24.13.

Rezolute Price Performance

NASDAQ:RZLT opened at $4.81 on Thursday. The company has a market cap of $278.69 million, a P/E ratio of -3.79 and a beta of 1.08. The stock’s fifty day moving average price is $4.88 and its two-hundred day moving average price is $4.85. Rezolute has a 1 year low of $0.92 and a 1 year high of $6.19.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RZLT. Marshall Wace LLP bought a new position in Rezolute in the second quarter valued at $4,503,000. Affinity Asset Advisors LLC increased its stake in Rezolute by 15.6% in the second quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock valued at $7,955,000 after acquiring an additional 250,000 shares during the last quarter. Geode Capital Management LLC increased its stake in Rezolute by 39.0% in the third quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock valued at $2,385,000 after acquiring an additional 137,905 shares during the last quarter. Exome Asset Management LLC grew its stake in shares of Rezolute by 24.7% during the third quarter. Exome Asset Management LLC now owns 352,056 shares of the company’s stock valued at $1,707,000 after buying an additional 69,656 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new position in shares of Rezolute during the second quarter valued at about $255,000. Institutional investors own 82.97% of the company’s stock.

Insider Activity at Rezolute

In other news, CFO Daron Evans bought 9,000 shares of Rezolute stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $4.60 per share, with a total value of $41,400.00. Following the completion of the purchase, the chief financial officer now directly owns 140,900 shares in the company, valued at $648,140. The trade was a 6.82 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 18.39% of the stock is owned by insiders.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.